Lv41
640 积分 2020-06-25 加入
Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial
7分钟前
待确认
Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial
7分钟前
待确认
Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study
19分钟前
待确认
Coronary Lipid Burden Indices Predict Non-Culprit Major Adverse Cardiac Events Independently of Novel LDL Estimates: Insights from the LRP Study
4天前
已完结
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials
4天前
已关闭
Impact of dual antiplatelet therapy duration on long-term outcomes following chronic total occlusion percutaneous coronary intervention
25天前
已关闭
Precision Management of Coronary In-Stent Restenosis
2个月前
已完结
Coronary revascularisation deferral based on quantitative flow ratio or fractional flow reserve: a post hoc analysis of the FAVOR III Europe trial
2个月前
已关闭
Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction
2个月前
已完结
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial
2个月前
已完结
皖公网安备34019202002308
